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Abstract
Treatment of patients with cerebral large vessel occlusion with thrombectomy and tissue plasminogen activator (tPA)
leads to incomplete reperfusion. Using rat models of embolic and transient middle cerebral artery occlusion (eMCAO
and tMCAO), we investigated the effect on stroke outcomes of small extracellular vesicles (sEVs) derived from rat
cerebral endothelial cells (CEC-sEVs) in combination with tPA (CEC-sEVs/tPA) as a treatment of eMCAO and tMCAO
in rat. The effect of sEVs derived from clots acquired from patients who had undergone mechanical thrombectomy on
healthy human CEC permeability was also evaluated. CEC-sEVs/tPA administered 4 h after eMCAO reduced infarct
volume by 36%, increased recanalization of the occluded MCA, enhanced cerebral blood flow (CBF), and reduced
blood-brain barrier (BBB) leakage. Treatment with CEC-sEVs given upon reperfusion after 2 h tMCAO significantly
reduced infarct volume by 43%, and neurological outcomes were improved in both CEC-sEVs treated models. CECsEVs/tPA reduced a network of microRNAs (miRs) and proteins that mediate thrombosis, coagulation, and inflammation.
Patient-clot derived sEVs increased CEC permeability, which was reduced by CEC-sEVs. CEC-sEV mediated suppression
of a network of pro-thrombotic, -coagulant, and -inflammatory miRs and proteins likely contribute to therapeutic
effects. Thus, CEC-sEVs have a therapeutic effect on acute ischemic stroke by reducing neurovascular damage.
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Introduction
Stroke is the fifth leading cause of death and the leading cause of disability worldwide. Cerebral large vessel
occlusion is the most disabling and life-threatening
cause of ischemic stroke.1,2 Approximately two-thirds
of eligible patients treated with tissue plasminogen activator (tPA) experience incomplete brain reperfusion.3
Mechanical thrombectomy performed within 24 hours
of stroke onset is now also the standard of care for the
treatment of acute ischemic stroke with large vessel
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occlusion.1,2,4–8 Reperfusion of the ischemic penumbra
is closely associated with good clinical outcomes.1,2
Although recanalization of the large vessel occlusion
by thrombectomy is achieved in >71% of patients, it
is often incomplete, and 50–52% of patients achieve
good neurological outcomes.1,2,4–6,9 Moreover, many
patients with large vessel occlusion exhibit rapid expansion of the ischemic core during the first few hours,
which leads to unfavorably large ischemic cores and
are not eligible to receive tPA or endovascular therapy.
Thus, there is a compelling need to develop therapies in
combination with tPA and thrombectomy to enhance
cerebral perfusion and augment therapeutic efficacy.
Also, therapies to block ischemic core expansion will
increase the number of patients who would be eligible
to receive tPA and thrombectomy.
Small extracellular vesicles (sEVs) including exosomes are endosomal origin membranous nanovesicles
that mediate intercellular communication by transferring cargo proteins, lipids, and genomic materials
including microRNAs (miRs) between source and
recipient cells.10,11 Our group was the first to demonstrate that exosomes derived from mesenchymal stromal cells given to rats 24 h after middle cerebral artery
occlusion (MCAO) substantially promote functional
recovery by exosomal miR-mediated brain remodeling
processes; however, these exosomes did not reduce
cerebral infarction.12–14 Others have subsequently
shown that treatment of acute stroke in animals with
sEVs derived from human neural stem cells or human
cardiosphere-derived cells alone or in combination with
tPA, respectively, reduces infarction and improves
functional outcomes.15 However, the therapeutic
effect of sEVs on acute stroke in particular in ischemic
stroke with large artery occlusion remains to be
investigated.
Using rat models of embolic MCAO (eMCAO) and
transient MCAO (tMCAO, ischemia/reperfusion),
both of which mimic patients with a large artery occlusion,12,27–29 the present study investigated the effect of
sEVs derived from human cerebral endothelial cells
(CEC-sEVs) in combination with tPA (CEC-sEVs/
tPA) and as co-therapy with mechanical reperfusion
on acute ischemic stroke, respectively. Our data indicate that CEC-sEVs/tPA given acutely after the onset
of eMCAO, or CEC-sEVs given upon reperfusion after
tMCAO substantially increase recanalization of the
embolic-occluded MCA and enhance downstream cerebral blood flow (CBF), and reduce blood-brain barrier
(BBB) leakage after eMCAO and significantly reduce
cerebral infarction and improve neurological outcomes
in both eMCAO and tMCAO stroke models compared
with their respective controls. Moreover, CEC-sEVs
administered intravenously cross the BBB and are
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preferentially internalized by cerebral endothelial
cells, astrocytes, and neurons in the ischemic
hemisphere.

Material and methods
All animal experimental procedures were approved by
the Institutional Animal Care and Use Committee
(IACUC) of Henry Ford Hospital in accordance with
the standards for humane animal care and use as set by
the Animal Welfare Act (AWA), the National Institute
of Health Guide for the Care and Use of Laboratory
Animals and ARRIVE (Animal Research: Reporting
in Vivo Experiments). Cerebral arterial clots were
acquired from patients with acute ischemic stroke
who underwent endovascular thrombectomy under an
Institutional Review Board (IRB) protocol approved
by the Institutional Review Board committee of
Henry Ford Hospital and adhered to the principles of
the Declaration of Helsinki (2008). All participants
were provided with an information sheet and all procedures were verbally explained in detail. All participants gave written informed consent after having the
opportunity to ask questions and receive appropriate
clarification. All experiments and outcome assessments
were performed by observers blinded to the treatments.

Isolation and characterization of sEVs from CECs
and arterial clots
For isolation of CEC-sEVs: CEC-sEVs were isolated
from the supernatant of cultured primary CECs harvested from healthy adult rats using differential ultracentrifugation according to the published protocol.16
Briefly, the supernatant was filtered through a
0.22 lm filter (Millipore-Sigma, MO) to sieve out the
dead cells and large growth debris. To remove additional debris, the filtered supernatant was centrifuged
at 10,000g for 30 minutes. Ultracentrifugation was
then performed at 100,000g for 3 hours to collect
sEVs. The numbers and sizes of particles in the pellet
were measured and analyzed using the nanoparticle
tracking analyzer (NTA), NanoSight N300 System,
(Merkel Technologies, Yehud, Israel). Morphology
and protein markers of CEC-sEVs were examined
using transmission electron microscopy (TEM) and
Western blot, respectively. For isolation of human
clot sEVs,17 patients with large vessel occlusion presenting within 24 hrs of acute ischemic stroke onset
were treated with mechanical thrombectomy according
to published guidelines.18 Those who qualified within
4.5 hours of onset were also treated with intravenous
tPA. Mechanical thrombectomy was performed using
an 8 French balloon guide catheter placed in the internal carotid artery or a 6 French guide catheter placed in
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the vertebral artery. Clot retrieval was then performed
utilizing a stent-retriever and proximal aspiration. If
this approach failed after 2–3 attempts then distal aspiration was performed using a commercially available
aspiration catheter often in combination with a stentretriever. The retrieved clots were immediately placed
in a fixative on ice and then stored in a refrigerator at
4 C. Cerebral arterial clots were homogenized within
12 h after the acquisition. Homogenization was centrifuged at 2,000 g for 15 mins and re-suspended in type3
collagenase (Rockland, PA) and protease inhibitors
(S8820, Millipore-Sigma, MO) to dissociate tissue and
to remove the remaining enzyme, respectively. Then,
sEVs were isolated and characterized following the
procedures used for CEC-sEVs.

Animal models
Male Wistar rats weighing 350–400 g and 275–300 g
were subjected to eMCAO or tMCAO, respectively.
Briefly, for eMCAO,19 a modified PE-50 catheter was
introduced into the lumen of the right external carotid
artery (ECA) through a small puncture. The catheter
was gently advanced from the ECA into the lumen of
the internal carotid artery (ICA) for 17–18mm. A single
clot (40 mm in length) was placed at the origin of the
MCA via the catheter. For tMCAO (2 h),20 a 4–0
monofilament nylon suture with its tip rounded by
high heat, was advanced from the right ECA into the
lumen of ICA for 18–19 mm until it blocked the origin
of the MCA. Two hours after MCAO, reperfusion was
achieved by withdrawal of the filament.
To acutely ascertain induction of stroke and in order
to minimize animal stress by not performing detailed
functional outcome measurements, the Longa fivepoint score was used to assay rat neurological deficits
at 1 h after MCAO.20 Rats with a score 2 were
enrolled in the present study because we have demonstrated that animals with a score 2 have a substantial
reduction of cerebral blood flow (CBF) in the MCA
territory after MCAO induced by a clot or a filament.21–24

Experimental protocol
To examine the effect of CEC-sEVs/tPA on acute
ischemic stroke, rats subjected to eMCAO were randomly assigned to the following treatment groups: 1)
CEC-sEVs alone, 2) tPA alone, 3) the combination of
CEC-sEVs and tPA, and 4) Saline. (n ¼ 10). CEC-sEVs
(1  1011 particles/rat) were administered intravenously
(IV) at 4 h and 24 h after MCAO. tPA (Genentech, San
Francisco, CA) was infused intravenously at a dose of
10 mg/kg as a 10% bolus starting at 4 h after eMCAO,
and the remainder was continuously infused over 30
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mins. We have demonstrated that tPA alone given at
2 h, but not at 4 h, after eMCAO to adult rats has a
therapeutic effect on acute embolic stroke.25,26 In the
present study, to examine whether CEC-sEVs enhance
tPA thrombolysis, a 4 h time point was selected. All
rats were sacrificed at 7 days after eMCAO for measurements of infarct volume. Additional sets of rats
were sacrificed at 26 h after eMCAO to assay residual
clot mass, cerebral vascular perfusion, BBB leakage,
and gross hemorrhage.27
To examine whether early administration of CECsEVs reduces ischemic core expansion, CEC-sEVs
(1  1011 particles/rat) were administered at 1 h after
eMCAO via a tail vein and ischemic rats treated with
saline were used as control (n ¼ 6). The development of
ischemic lesion was measured by means of MRI at 2 h
and 24 h after stroke onset.
To examine whether CEC-sEVs reduce ischemic
lesion, CEC-sEVs (1  1011 particles/rat) were administered via the internal carotid artery (IA) immediately
following the withdrawal of the filament at 2 h after
tMCAO (n ¼ 6). A second dose of CEC-sEVs
(1  1011 particles/rat) was administered at 24 h after
tMCAO via a tail vein. Rats subjected to tMCAO
treated with the same volume of saline were used as a
control group (n ¼ 6). All rats were sacrificed at 7 days
after tMCAO for measurements of infarct volume.

Behavioral tests
An array of behavioral tests to measure sensorimotor
function were performed at 1 day and 7 days after
ischemia in both eMCAO and tMCAO models by
observers blinded to the treatments. Modified neurological severity score (mNSS) is a composite of motor,
sensory, reflex, and balance tests.28 Neurological function was graded on a scale of 0 to 18 (normal score, 0;
maximal deficit score, 18). The Adhesive removal test
which records the mean time required to remove an
adhesive paper from individual front paws provides
an index of somatosensory deficits.29 The Foot-fault
test detects forelimb dysfunction30 by measuring the
total number of steps (movement of each forelimb)
and the number of foot faults when the rat crossed
the grid.

Magnetic resonance imaging (MRI) measurements
MRI measurements were performed with a 7-T preclinical MRI scanner (Bruker-Biospin, Billerica, MA).
MRI measurements were performed at 1 h, 4.55 h,
and 24 h after the onset of eMCAO, and included magnetic resonance angiography, perfusion-weighted imaging, apparent diffusion coefficient (ADC), and
transverse relaxation time (T2).31 Ischemic lesion
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volume was calculated by means of a threshold value of
the mean ADC value with two times the standard deviation of the contralateral hemisphere tissue.31

Histopathologic analysis
To measure infarct volumes, rats at 7 days after
eMCAO and tMCAO were sacrificed by transcardial
perfusion with heparinized saline followed by 4% paraformaldehyde. Brains were removed and fixed in 4%
paraformaldehyde. Infarct volume was measured on 7
hematoxylin and eosin (H&E) stained coronal sections
using a Micro Computer Imaging Device (MCID)
system, as previously described.19
To measure the residual embolus at the origin of
occluded MCA, rats (n ¼ 6/group) were sacrificed at
26 h after eMCAO by transcardial perfusion with
saline and followed with 4% paraformaldehyde. The
residual embolus at the origin of the MCA was
imaged with a digital camera and the area of residual
embolus (mm2) was measured, as previously described
with some modifications.27 The present study directly
measured the size of the entire residual embolus, while
in our prior study, a residual pre-fluorescently labeled
clot was measured.27
Gross hemorrhage, defined by identification of
blood accumulation in brain tissue with an unaided
naked-eye was measured on H&E-stained coronal sections in rats sacrificed at 26 h after eMCAO.27 The
incidence of gross hemorrhage is presented as the percentage of rats with a visually identified gross hemorrhage in each experimental group (n ¼ 6/group).

Measurement of plasma-perfused cerebral vessels
To measure blood plasma perfused cerebral blood vessels, fluorescein isothiocyanate (FITC)-dextran (2x106
molecular weight, Sigma, 50 mg/rat, IV) was administered to rats 26 h after eMCAO (n ¼ 6/group). Rats
were sacrificed 15 min after FITC-dextran injection
and 3 coronal vibratome sections (100 mm/section)
obtained from the center of the ischemic lesion
(bregma 0.2 to 0.8 mm) were analyzed using the
MCID system, as previously described.27 The area
of FITC-dextran perfused blood vessels was
measured and presented as the percentage of FITCdextran perfused area within the territory supplied by
the MCA.

Measurement of Evans blue extravasation
Parenchymal Evans blue extravasation was measured
in rats 26 h after eMCAO, as previously described
(n ¼ 3/group).27 Briefly, Evans blue (2% in saline;
1 ml/rats) was iv injected 24 h after eMCAO. Rats
were transcardially perfused with saline at 2 h after
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the injection. Each hemisphere was weighed, homogenized in 2 mL 50% trichloroacetic acid, and centrifuged. The fluorescence intensity in the supernatant
was determined using a microplate fluorescence
reader (excitation 620 nm and emission 680 nm). The
amount of Evans blue within the ipsilateral hemisphere
was quantified based on a standard curve generated
with the external standards dissolved in the same solvent and is presented as mg/g of tissue.

Immunohistochemistry and Western blot
Immunofluorescent staining was performed on coronal
sections at the center of the ischemic lesion obtained
from rats sacrificed at 26 h after eMCAO. Brain tissues
were harvested from the peri-ischemic lesion including
cortex and subcortex. The following primary antibodies were used: goat monoclonal antibody (mAb)
against fibrinogen/fibrin (1:200, YNGRaFbg7S,
Accurate Chemical & Scientific), mouse mAb against
endothelial barrier antigen (EBA, 1:200, SMI71,
Sternberger Monoclonals Inc), rabbit polyclonal antibody (pAb) anti-thrombocytes (1:200, CLA51440,
Cedarlane). EBA immunoreactivity was used to identify cerebral blood vessels. For quantification, the numbers of vessels with fibrin/fibrinogen and thrombocytes
immunoreactivity were counted throughout the territory supplied by the right MCA and are presented as the
density of immunoreactive vessels relative to the scan
area (mm2).
Western blots were performed according to published methods.32 Briefly, equal amounts of total
protein for each sample were loaded on 10%
SDS-polyacrylamide gels. The blots were subsequently
probed with the following primary antibodies: rabbit
pAb against TLR2 or TLR4 (1:1,000, ab213676, or
ab13556, Abcam), rabbit pAb against tissue factor
(TF, 1:1,000, ab104513, Abcam), rabbit pAb against
PAI-1 (1:1,000, ab66705, Abcam), rabbit pAb against
P-selectin (1:1,000, PA5-87043, Invitrogen), rabbit pAb
against HMGB1 (1:1,000, 3935 s, Cell Signaling
Technology), rabbit pAb against CD63 (1:1,000,
ab118307, Abcam), mouse mAb against Alix (1:1,000,
MA1-83977, Thermo Fisher Scientific), rabbit mAb
against ICAM-1 (1:1000, ab53013; Abcam), rabbit
pAb against zonula occludin-1 (ZO1, 1:1,000,
ab96587; Abcam), and rabbit mAb against phosphorylated NF (nuclear factor)-jB p65 at Ser536 (pp65
[phosphorylated p65], 1:1,000, 3033S; Cell Signaling
Technology) and mouse mAb against b-actin
(1:5,000, ab8226; Abcam). Western blots were performed from at least 3 individual experiments.
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CEC integrity assay
Healthy human CECs were purchased from ScienCell
(Cat#1,000; Carlsbad, CA). The endothelial monolayer
barrier assay was performed according to our published method.33 Briefly, endothelial cells (passage 2
to 4) were cultured for 7 days at a density of 5  104
per well and were then seeded as monolayer onto the
inner chamber of trans-well insert (Corning). Small
EVs were added into the culture medium for 48 h.
Fluorescent-conjugated dextran (0.5 mg/mL, 70 kDa,
D1830; Thermo Fischer Scientific) was then added to
the top of the trans-wells for 30 minutes. Fluorescent
signals in the bottom medium were then measured
using a plate reader at excitation and emission wavelengths of 595 nm and 615 nm, respectively. Transendothelial permeability was calculated as % signals¼
(optical density experimental-optical density vehicle)/
optical density vehicle  100. All data were obtained
from 3 individual experiments.

Analysis of miRs and Bioinformatics analysis
miRs were isolated from rat primary CECs and CECsEVs by means of the miRNeasy Mini kit (Qiagen,
Valencia, CA, USA) following the manufacturer protocol. Quantitative RT-PCR was performed on an ABI
7000 and ABI ViiATM 7 PCR instrument (Applied
Biosystems, Foster City, CA). miRs were reversely
transcribed with the miR Reverse Transcription kit
(Applied Biosystems, Foster City, CA) and amplified
with the TaqMan miR assay (Applied Biosystems,
Foster City, CA), which is specific for mature
miRNA sequences. U6 snRNA was used as an internal
control. Analysis of gene expression was carried out by
the 2DDCt method. For the miR array, quality control of the total RNA samples was assessed using UV
spectrophotometry and agarose gel electrophoresis.
The samples were DNAse digested and lowmolecular-weight (LMW) RNA was isolated by ultrafiltration through YM-100 columns (Millipore,
Billerica, MA) and subsequent purification using the
RNeasy MinElute Clean-Up Kit (Qiagen, Valencia,
CA). The LMW RNA samples were 30 -end-labeled
with biotin dye using the FlashTagTM Biotin RNA
Labeling Kits (Genisphere, Hatfield, PA). Labeled
LMW RNA samples were hybridized to the
MicroRNA microarrays according to conditions recommended in the Flash Taq RNA labeling Kit
manual. The microarrays were scanned on an Axon
Genepix 4000B scanner (Affymetrix Inc), and data
were extracted from images using GenePix V4.1 software. miRNA QC Tool (Affymetrix Inc). Microarray
data is MIAME compliant and the raw data have been
deposited in the Gene Expression Omnibus database.

5
Ingenuity Pathway Analysis (IPA) software
(QIAGEN; Hilden, Germany) was used for signaling
pathway analysis. Gene and miR names were imported
into IPA and processed using the core analysis tool.
Using the IPA knowledge base, networks of experimental proteins and miRs were built. Networks were
graphically visualized as hubs (proteins and miRs)
and edges (the relationship between proteins and
miRs).

GFP-CEC-sEVs construction and sEV distribution
To examine the distribution of intravenously administered CEC-sEVs in the ischemic brain, CEC-sEVs carrying CD63-GFP (GFP-sEVs) were generated
according to our published protocols.34 Briefly, CECs
were transfected with a plasmid carrying pEGFPCD63 vector (CD63-pEGFP C2, a gift from Paul
Luzio, Addgene plasmid # 62964) by means of electroporation (Nucleofector system, program U11, Lonza).
CD63 is a membrane protein marker of exosomes.35
The presence of GFP proteins in sEVs (GFP-sEVs)
was examined by means of Western blot.
To track the brain distribution of CEC-sEVs, immunogold based TEM imaging was used. Briefly, GFPCEC-sEVs (3x1011 particles/mouse) were intravenously
injected via a tail vein into the rat at 4 h after eMCAO
(n ¼ 3). Ischemic rats (n ¼ 3) that received naı̈ve-CECsEVs were used as a control. Two hours after the injection, the rat brain was collected and fixed by 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer for
24 hours at 4 C. The brain tissues were post-fixed by
1% Osmiumtetroxide/1.5% Potassium ferrocyanide for
1 hour at room temperature and embedded into the
resin mixture. The ultrathin sections (85 nm) were
obtained and mounted on nickel grids. Immunogold
staining was then performed with a 2% anti-GFP
rabbit monoclonal antibody (G10362, ThermoFisher)
and 10 nm gold conjugated streptavidin (25,269 EMS).
The grids were imaged under TEM (JEM-1400Flash,
JEOL).

Statistical analysis
Sample size was determined based on our preliminary
data which showed an effect size of 6.26 and 0.99 on 2
and 7 days infarction, respectively, between tPA alone
and tPA in combination with CEC-sEVs. Considering
alpha ¼ 0.05, a two-sided test, 10/group for 7 days and
6–8/group for earlier assessments, there is an 80%
power to detect effect sizes of 1.48 and 1.68, respectively, assuming equal space of means.
Data were evaluated for normality by the ShapiroWilk test and ranked data were used for behavioral
data analysis since the modified neurological severity
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score data were not normally distributed. Using the
intention-to-treat approach, if an animal died before
the designated endpoint, the worse observed behavioral
test score was used. The Global test using the
Generalized Estimating Equation was implemented to
test the treatment effect on the behavioral outcome
measured from 3 behavioral tests at each time point.
Additionally, statistical analysis was performed using
the Statistical Package for the Social Sciences (SPSS,
version 11.0; SPSS Inc, Chicago, IL). One-way
ANOVA with post hoc Bonferroni tests was used
when comparing more than two groups. The student’s
t-test was used when comparing two groups. All data
are presented as mean  standard deviation. A p-value < 0.05 was considered significant.

filament and initiation of IA injection. These rats
were excluded from experimental data analysis because
they died before the treatments. Rats subjected to
tMCAO
were
treated
with
CEC-sEVs
(1  1011particles/rat) via the internal carotid artery
(IA) immediately following the withdrawal of the filament at 2 h after MCAO. A second dose of CEC-sEVs
was given 24 h later via a tail vein (IV). We found that
CEC-sEVs significantly reduced infarct volume by
37% and improved neurological function compared
with saline (Figure1(d) and (e)). These data indicate
that CEC-sEVs adjunctive with tPA initially administered 4 h post eMCAO and CEC-sEVs treatment of
tMCAO given upon reperfusion have a therapeutic
effect for acute ischemic stroke.

Results

Early intravenous administration of CEC-sEVs
suppresses ischemic lesion expansion

CEC-sEVs significantly reduce infarct volume and
improve neurological outcomes in the rat
CEC-sEVs were isolated from the supernatant of cultured primary rat CECs using ultracentrifugation.16 We
previously demonstrated that tPA alone given at 2 h,
but not at 4 h, after eMCAO to adult rats has a therapeutic effect on acute stroke.25,26 To examine whether
CEC-sEVs enhance the therapeutic effect of tPA given
4 h after eMCAO, CEC-sEVs (1  1011particles/rat) in
combination with tPA (10 mg/kg) were administered via
a tail vein to adult male rats 4 h after eMCAO and a
second dose of CEC-sEVs alone was given 24 h after
eMCAO. All rats exhibited severe neurological deficits
with a mean score of 2 as assayed on Longa five-point
score before the initial treatment.20 During the experimental period, one rat died at 48 h after eMCAO in the
saline group (10%), two at 24 h and 48 h, respectively, in
the tPA group (20%), two at 24 h and 48 h, respectively,
in the sEVs group (20%), and zero in the tPAþsEVs
group. Compared to the saline treatment, monotherapy
of tPA did not significantly reduce neurological deficits
measured with an array of well established behavioral
tests, although spontaneous recovery occurred
(Figure 1(a)). CEC-sEVs alone also did not significantly
improve neurological outcomes (Figure 1(a)). In contrast, CEC-sEVs/tPA significantly reduced neurological
deficits and reduced infarct volume by 40% compared
to tPA alone and saline (Figure1(a) and (c)). The combination of CEC-sEVs with tPA did not significantly
increase gross hemorrhage in the ischemic rat compared
to saline or monotherapy of tPA (Figure1(b)).
We then examined the effect of CEC-sEVs on ischemia and reperfusion to mimic thrombectomy in rats
subjected to tMCAO. Two out of 8 rats (25%) from
the saline group and 1 out of 7 (14%) from the
CEC-sEV group died during withdrawal of the

The ischemic core expands during the acute ischemic
stage, which results in a reduction of the ischemic penumbra.36 To examine whether early administration of
CEC-sEVs reduces ischemic core lesion expansion, we
administered CEC-sEVs (I.V) to ischemic rats at 1 h
after eMCAO and then examined the dynamic expansion of the ischemic lesion 2 and 24 h after eMCAO
using ADC and T2 weighted MRI images. CEC-sEVs
monotherapy led to ischemic lesion expansion by 38%
from 24.3  2.0% of volume at 2 h to 33.5  7.0% at
24 h, whereas saline treatment resulted in lesion expansion of 80% from 23.5  3.0% at 2 h to 42.2  7.0% at
24 h of eMCAO. The difference in ischemic lesion
expansion between these two groups was significant
(p < 0.05). These data suggest that the early administration of CEC-sEVs attenuates ischemic core lesion
expansion, which would preserve a large penumbra
and thus may permit more patients to be eligible for
tPA and thrombectomy treatments.1

CEC-sEVs/tPA promotes recanalization, increase
CBF and downstream vascular patency, and reduce
BBB leakage
To examine the effect of CEC-sEVs/tPA on recanalization of the occluded MCA and its downstream microvascular perfusion, additional experiments were
performed on rats with eMCAO. The combination of
CEC-sEVs with tPA given 4 h after eMCAO significantly reduced the embolus size at the origin of the
occluded MCA compared with tPA monotherapy
when the rats were sacrificed at 24 h after eMCAO
(Figure2(a)). To examine downstream non-occluded
microvessels, we injected FITC-dextran to the rats via
a tail vein at 24 h after eMCAO and sacrificed the rats
15 min after the injection for FITC-plasma to perfuse
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Figure 1. The effects of CEC-sEVs/tPA or CEC-sEVs given upon reperfusion to rats subjected to eMCAO or tMCAO, respectively.
The effect of CEC-sEVs/tPA on an array of behavioral tests (A), brain hemorrhage (B), and infarct volume (C) of rats subjected to
eMCAO when tPA and/or CEC-sEVs were administered 4 h after eMCAO. Panel C shows representative images of H&E stained brain
coronal sections and their quantitative data. N ¼ 10/group, *p < 0.05; **p < 0.01, and ***p < 0.001 vs Saline. The effect of CEC-sEVs
administered upon reperfusion at 2 h of tMCAO on an array of behavioral tests (D) and infarct volume (E) of rats subjected to
tMCAO. N ¼ 6/group, ***p < 0.001 vs Saline.

all open cerebral vessels.23,24,37 3 D LSCM analysis
showed that the combination treatment sEVs with
tPA given 4 h after eMCAO significantly increased
FITC-dextran perfused downstream microvessels
(Figure2(b)). The combination therapy also significantly reduced BBB leakage measured by Evans blue,
parenchymal fibrin deposition, and platelet accumulation compared with tPA alone (Figure 2(c) to (e)). MRI

measurement in the same rat before and after the treatment showed that CEC-sEVs/tPA promoted recanalization of the occluded MCA as measured with
magnetic resonance angiography, increased downstream CBF measured with perfusion-weighted imaging, and decreased ischemic lesion measured with
ADC, and T224 24 h after eMCAO compared with
tPA monotherapy (Figure 3). Collectively, these data
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Figure 2. The effect of CEC-sEVs/tPA on thrombosis and BBB leakage. CEC-sEVs/tPA significantly reduced embolus size at the origin
of the occluded MCA (A), downstream FITC-plasma-perfused microvessels (B), Evans blue leakage (C), extravascular fibrin deposition
assayed by double immunofluorescent staining (D, green), and intravascular platelet aggregation assayed by double immunofluorescent
staining (E, green). The red color in panels D and E is EBA immunoreactive vessels. N ¼ 6/group, *p < 0.05 and **p < 0.01 vs Saline.
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Figure 3. The effect of CEC-sEVs/tPA on recanalization, CBF, and ischemic lesion. Representative MRI images (A) show recanalization of occluded MCA measured by magnetic resonance angiography (MRA, arrow), CBF by perfusion-weighted image, ischemic
lesion by ADC and T2 at pre-treatment (1 h), immediately after the treatment (4.5-5 h) and post-treatment (24 h) in representative
rats subjected to eMCAO and treated with tPA or treated with tPA in combination with CEC-sEVs (CEC-sEVs/tPA). Panel B shows
areas with low CBF and infarct volume measured by T2. N ¼ 6/group, *p < 0.05 and ***p < 0.001 vs tPA monotherapy.

strongly suggest that CEC-sEVs facilitate tPA-induced
thrombolysis of the occluded MCA, increase downstream microvascular reperfusion, and reduce BBB
leakage and infarction, which consequently lead to
improvements of neurological function.

CEC-sEVs elevate a set of miRs and reduce prothrombotic and BBB leakage proteins in CECs
To examine the effect of CEC-sEVs/tPA on miRs, we
analyzed miRs in primary CECs isolated from the
ischemic blood vessels of rats subjected to 24 h
eMCAO using qRT-PCR. We found that CECs harvested from ischemic rats treated with saline or tPA
exhibited significantly reduced miR-19a, -21, and
-146a expression compared with CECs from nonischemic rats, whereas the endothelial cells from rats
treated with CEC-sEVs/tPA did not show a significant
reduction of these three miRs compared with CECs
from non-ischemic rats (Figure 4(a)). Western blot
analysis of the endothelial cells from the same sets of
rats showed that compared with non-ischemic, saline or
tPA treatment increased levels of TLR4, ICAM-1,
PAI-1, TF, and pNF-jB, and reduced ZO1, which
were reversed by the combination CEC-sEVs/tPA
treatment (Figure 4(b)). Bioinformatics analysis
revealed that the altered miRs and proteins form a network that promotes vascular injury, thrombogenicity,
and BBB leakage38–40 (Figure 4(c)). Using miR arrays,

we analyzed CEC-sEVs cargo miRs and found that
miR-19a, -21 and -146a were among the top 10
enriched miRs within CEC-sEVs including miR-328a,
-483, -125 b, -344a, -211, and let-7b and let-7c. These
data suggest that miRs and proteins altered by CECsEVs contribute to the therapeutic effect of CEC-sEVs
on acute stroke.
To investigate whether the beneficial effects of CECsEVs on cerebral endothelial cell function observed
after stroke in rodents are present in human CECs
and whether human CEC-sEVs provide a vascular
therapeutic effect, we isolated sEVs from
thrombectomy-retrieved arterial thrombi of patients
with acute ischemic stroke. These patient arterial
clots derived sEVs had doughnut morphology and a
mean diameter of 85.6  1.7 nm assayed by TEM and
NTA and showed sEV marker proteins, CD63, and
Alix (Figure 5). Using an in vitro trans-endothelial permeability assay,41 we then examined the effect of
patient-clot-derived sEVs on endothelial permeability.
Incubating healthy human CECs with patient-clotderived sEVs significantly increased endothelial cell
leakage (Figure 5). Moreover, the clot-derived sEVs
substantially reduced endothelial cell miR-19a, -21,
and -146a and increased proteins of TLR4, ICAM-1,
PAI-1, TF, and NF-jB (Figure 5). Importantly, the
concurrent addition of sEVs derived from healthy
human CECs with the clot-derived sEVs significantly
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Figure 4. The effect of CEC-sEVs/tPA on cerebral vascular miRs and proteins. CEC-sEVs/tPA significantly upregulated miR-19a, -21,
and -146a assayed by qRT-PCR (A). Panel B shows representative Western blot images and their quantitative data of protein levels of
TLR4, ICAM1, NF-KB-p65, PAI-1, TF, and ZO-1 in rats subjected to eMCAO and treated with saline, tPA alone, and CEC-sEVs/tPA.
CECs derived from non-ischemic rats were used as a control. Panel C shows a network of miR-19a, 21, and 146a and their putative
target genes generated by IPA. N ¼ 6/group, *p < 0.05 vs Saline and #p < 0.05 vs indicated group.

reduced patient-clot-derived sEV increased endothelial
cell leakage and reversed miRs and proteins altered by
patient-clot-derived sEVs (Figure 5). These data provide evidence that patient-clot-derived sEVs promote
thrombosis and BBB leakage, which can be reduced
by healthy human CEC-sEVs.

CEC-sEVs intravenously administered cross the BBB
and are internalized by CECs, astrocytes, and
neurons
To track the brain distribution of intravenously administered CEC-sEVs, we treated rats subjected to 4 h of
eMCAO with CEC-sEVs isolated from healthy CECs
transfected with CD63-GFP plasmids (GFP-CECsEVs, Figure 6). Confocal microscopic images showed
that GFP signals were primarily found in cells lining
the cerebral blood vessels and neurons in the ipsilateral
hemisphere at 2 h after the IV injection (Figure 6).
TEM analysis revealed that GFP-immunogold particles were localized to endothelial cells of cerebral
microvessels with intact tight junction, astrocyte footprocesses, and neurons (Figure 6). Omitting the primary antibody against GFP resulted in no detection of
GFP-gold particles. These data provide evidence that
CEC-sEVs cross the BBB and that astrocytes and

neurons in the ischemic hemisphere can internalize
CEC-sEVs.

Discussion
The present study demonstrates that CEC-sEVs either
in combination with tPA or given immediately upon
reperfusion enhance thrombolysis and recanalization
and reduce BBB leakage in a rat model of embolic
stroke and reduce cerebral infarction and improve neurological outcomes after both eMCAO and tMCAO,
i.e., in rat models of ischemic stroke with a large arterial occlusion. Intravenously administered CEC-sEVs
cross the BBB and are internalized by the neural cells
in the ischemic brain. CEC-sEVs/tPA substantially
increase a set of CEC-sEV cargo-enriched miRs in
CECs, and significantly reduce tPA- and ischemiaincreased proteins that mediate thrombosis and BBB
leakage. Importantly, a therapeutic effect of CECsEVs was also observed in human cerebral endothelial
cells impaired by patient arterial clot derived sEVs.
Together, the present study provides evidence that
CEC-sEVs significantly reduce stroke-induced neurovascular damage and improve neurological outcomes.
Mechanical endovascular thrombectomy and tPA
are now the standards of care for the treatment of
patients with acute ischemic stroke who meet inclusion
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Figure 5. The effect of sEVs derived from arterial clots of patients with acute ischemic stroke on human cerebral endothelial
permeability. Representative TEM and Western blot images show that clot derived sEVs have cup-shaped morphology (A), proteins of
CD63 and Alix (B), and clot sEVs distribution (C). Panel D shows a schematic cerebral endothelial cell permeability assay and
quantitative data of permeability changes in human CECs treated with saline, clot derived sEVs alone (clot-sEVs) or clot derived sEVs
with sEVs derived from healthy human cerebral endothelial cells (clot-sEVs/CEC-sEVs), (n ¼ 6/group). Panel E shows qRT-PCR data of
miR-19a, -21, and -146a in CECs after the specified treatments, (n ¼ 5/group). Panel F and G show representative Western blot
images of individual proteins in CECs and their quantitative data after the specified treatments (n ¼ 5/group). *p < 0.05 vs saline and
#p < 0.05 vs indicated group. P-sel ¼P-selectin.

criteria.1,2,4–8 Patients with timely reperfusion of the
ischemic lesion have increased liklihood of achieving
good clinical outcomes.1,2 Using models of eMCAO
in the rhesus macaques, mouse, and rat, recent studies
demonstrate that enhancement of reperfusion by tPA
in combination with selective intra-arterial cooling and
an angiotensin type 2 receptor agonist substantially
reduces and improves neurovascular damage and neurological function, respectively.42–44 We and others previously demonstrated that exosomes derived from
mesenchymal stem cells and other cell types enhance
brain remodeling during stroke recovery.12–14
However, studies that have used sEVs for enhancing
brain perfusion after acute ischemic stroke with a
large artery occlusion are limited.12 The present
study, for the first time, demonstrates that CEC-sEVs

robustly enhance tPA-induced thrombolysis and
robustly reduced BBB leakage and infarction in a
model of eMCAO. The evolution of the hypoperfused
penumbra to irreversible infarction leads to ischemic
core expansion, which results in many patients with
large vessel occlusion being not eligible to receive tPA
or endovascular therapy.2,8 The present study demonstrates that when rats are treated with CEC-sEV monotherapy early (1 h) after the onset of eMCAO, the
expansion of the ischemic core is substantially attenuated. Collectively, these data indicate that CEC-sEVs
substantially reduce stroke-induced neurovascular
damage. The present study also provides the first evidence that sEVs derived from arterial clots of patients
with acute ischemic stroke impair cerebral endothelial
cell permeability, whereas sEVs derived from healthy
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Figure 6. Brain distribution of intravenously administered GFP-CEC-sEVs. Representative orthogonal confocal images showed GFP
signals in CECs (A) and neurons (B) after intravenous administration (IV) of GFP-CEC-sEVs. Representative TEM images showed that
GFP positive gold particles from cerebral blood vessel lumen crossed endothelial cells and reached astrocyte foot processes (C, D,
arrows) and within the cytoplasm and multivesicular body (MVB) of neurons (E, arrows). VBM in D ¼ vascular base membrane. Bars in
C ¼ 100 nm, D and E ¼ 200 nm, respectively.

human CECs attenuate the effect of patient clotderived sEVs on cell permeability. These in vitro data
suggest that in addition to arterial thrombi, sEVs from
the clot damage CECs, and that human CEC-sEVs
have a therapeutic effect on injured CECs as do rat
CEC-sEVs. Compounds employed for the treatment
of acute ischemic stroke need to meet multiple requirements including facilitation of recanalization, enhancement of fibrinolysis and thrombosis, vascular
stabilization, and increase of BBB integrity and amplification of neuroprotection.4,6,45 Thus, the treatment
with CEC-sEVs as adjunctive therapy with tPA and/
or mechanical thrombectomy potentially augment neuroprotection by robustly reducing neurovascular
damage of acute ischemic stroke.
EVs can transfer their cargo biological materials
including miRs to recipient cells, consequently leading
to changes in recipient cell function.46,47 The present
study shows that the CEC-sEVs/tPA results in the

upregulation of a set of miRs (miR-19a/21/146a),
which are inversely associated with protein levels of
TLR4, ICAM-1, PAI-1, and TF in CECs. The altered
miRs and associated proteins form a network that
mediates thrombosis, inflammation, and BBB integrity.48,49 Injured endothelial cells upregulate TF, ICAM1, HMGB1, and P-selection, which amplify vascular
injury and thrombogenicity by forming neutrophil
extracellular traps (NETs).38–40 The TLR signaling
pathway mediates cerebral endothelial cell function
and regulates the formation of NETs.39 Formation of
NETs in the cerebral artery is highly associated with
the worse neurological outcomes of patients with acute
stroke.48 Among miRs, miR-146a is a well characterized miR that targets TLR signaling.50,51 We previously
demonstrated that elevation of miR-146a in cerebral
endothelial cells reduces fibrin-increased cell permeability by targeting TLR2 and TLR4.52 MiR-21 also
targets TLR4,53 while miR-19 exerts anti-thrombotic

Li et al.
effects by suppressing genes of TF and PAI-1.54,55
Importantly, miR-19, -21, and -146a are well conserved
between human and rodent.54,55 Collectively, the present study suggests that the CEC-sEV cargo miRs
likely contribute to the therapeutic effect of CECsEVs on the improvement of neurovascular function,
which has the potential for clinical translation.
However, additional studies are warranted to validate
this premise and to investigate the role of CEC-sEV
cargo proteins in the observed beneficial effects of
CEC-sEVs on acute ischemic stroke.
Our ultrastructural data provide supportive evidence that intravenously administered CEC-sEVs
cross the BBB and are internalized by neurons and
other parenchymal cells. Localization of CEC-sEVs
within astrocyte foot-processes suggests that CECsEVs act on astrocytes to improve BBB integrity.
Additionally, CEC-sEVs reach injured neurons, which
potentially protects ischemic damaged neurons. Thus,
in addition to CECs, CEC-sEVs act on astrocytes and
neurons, which may contribute to the therapeutic effect
of CEC-sEVs on reducing ischemic neurovascular
damage. However, further studies are warranted to
investigate the contributions of individual cell types
to the improved neurological function.
In summary, the present study indicates that CECsEVs have a therapeutic effect on acute ischemic stroke
in the rat by facilitating recanalization, enhancing fibrinolysis and thrombolysis, enhancing BBB integrity,
reducing inflammation, and amplifying neuroprotection.45 These data are also of importance in light of
recent findings showing that COVID19 patients with
acute ischemic stroke had robust thrombosis, inflammation, and worse stroke outcome.56–59
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